Literature DB >> 21457743

Increased plasma levels of thioredoxin-1 in patients with first episode psychosis and long-term schizophrenia.

Björn Owe-Larsson1, Karin Ekdahl, Tobias Edbom, Urban Osby, Håkan Karlsson, Christer Lundberg, Mathias Lundberg.   

Abstract

Excessive level of radicals and/or dysfunctional antioxidant response, oxidative stress, is implicated in the pathogenesis of schizophrenia. A condition of oxidative stress has been detected in the brain, peripheral tissues and fluids including plasma. Plasma thioredoxin-1 (Trx1) is well characterized and a putative marker for oxidative stress and recently shown to be increased in plasma at the onset of schizophrenia. The present study aimed to explore whether Trx1 can be used as a marker to identify schizophrenic patients at the time-point when patients have their first episode of psychosis as compared to patients with long-term schizophrenia and mentally healthy patients, respectively. Plasma samples obtained from 18 patients at first episode of psychosis, from 49 long-term schizophrenic patients and from 20 mentally healthy controls (admitted with minor physical injury to the general ward) where analyzed by ELISA for Trx1. The patients with first episode of psychosis were diagnosed at least 6 months later and shown to constitute various psychotic syndromes, including schizophrenia, or affective disorder. The concentration of Trx1 in the patients with first episode of psychosis was 1.5 ± 1.0 ng/ml and 0.8 ± 0.6 ng/ml in controls. In the long-term schizophrenic patients the plasma concentration was 1.5 ± 0.7. The differences between the groups of acute psychotic or long-term schizophrenia patients to controls were significant (p < 0.016 and p < 0.001, respectively). Our data indicate that Trx1 may not be used as an early marker to identify schizophrenic patients in a mixed population of first episode psychotic patients. Further, Trx1 did not discriminate with reliable accuracy patients with psychotic disorder from mentally healthy controls on an individual basis due to overlap in levels of Trx1. However, our observations show that psychotic patients in general are in a significant long-term condition of oxidative stress, with possible implications for the profound morbidity and mortality found in this patient population.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21457743     DOI: 10.1016/j.pnpbp.2011.03.012

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  10 in total

Review 1.  Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics.

Authors:  Chi-Yu Lai; Elizabeth Scarr; Madhara Udawela; Ian Everall; Wei J Chen; Brian Dean
Journal:  World J Psychiatry       Date:  2016-03-22

2.  Neuroendocrine profile in a rat model of psychosocial stress: relation to oxidative stress.

Authors:  Marilena Colaianna; Stefania Schiavone; Margherita Zotti; Paolo Tucci; Maria Grazia Morgese; Liselotte Bäckdahl; Rikard Holmdahl; Karl-Heinz Krause; Vincenzo Cuomo; Luigia Trabace
Journal:  Antioxid Redox Signal       Date:  2013-04-20       Impact factor: 8.401

3.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

Review 4.  Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects.

Authors:  Regina F Nasyrova; Dmitriy V Ivashchenko; Mikhail V Ivanov; Nikolay G Neznanov
Journal:  Front Physiol       Date:  2015-05-11       Impact factor: 4.566

5.  Untargeted screening for novel autoantibodies with prognostic value in first-episode psychosis.

Authors:  A Zandian; L Wingård; H Nilsson; E Sjöstedt; D X Johansson; D Just; C Hellström; M Uhlén; J M Schwenk; A Häggmark-Månberg; O Norbeck; B Owe-Larsson; P Nilsson; M A A Persson
Journal:  Transl Psychiatry       Date:  2017-07-25       Impact factor: 6.222

6.  NADPH oxidase elevations in pyramidal neurons drive psychosocial stress-induced neuropathology.

Authors:  S Schiavone; V Jaquet; S Sorce; M Dubois-Dauphin; M Hultqvist; L Bäckdahl; R Holmdahl; M Colaianna; V Cuomo; L Trabace; K-H Krause
Journal:  Transl Psychiatry       Date:  2012-05-08       Impact factor: 6.222

Review 7.  Thioredoxin system regulation in the central nervous system: experimental models and clinical evidence.

Authors:  Daniela Silva-Adaya; María E Gonsebatt; Jorge Guevara
Journal:  Oxid Med Cell Longev       Date:  2014-02-27       Impact factor: 6.543

8.  Methodological aspects of ELISA analysis of thioredoxin 1 in human plasma and cerebrospinal fluid.

Authors:  Mathias Lundberg; Sophie Curbo; Kathrin Reiser; Thomas Masterman; Sten Braesch-Andersen; Irene Areström; Niklas Ahlborg
Journal:  PLoS One       Date:  2014-07-30       Impact factor: 3.240

Review 9.  Inflammation, Stress Response, and Redox Dysregulation Biomarkers: Clinical Outcomes and Pharmacological Implications for Psychosis.

Authors:  Stefania Schiavone; Luigia Trabace
Journal:  Front Psychiatry       Date:  2017-10-25       Impact factor: 4.157

10.  Redox dysregulation as a link between childhood trauma and psychopathological and neurocognitive profile in patients with early psychosis.

Authors:  Luis Alameda; Margot Fournier; Ines Khadimallah; Alessandra Griffa; Martine Cleusix; Raoul Jenni; Carina Ferrari; Paul Klauser; Philipp S Baumann; Michel Cuenod; Patric Hagmann; Philippe Conus; Kim Q Do
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-19       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.